- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04512794
Pulmonary Vein Isolation Plus Left Atrial Slow Zone Mapping and Ablation (PLASZMA)
Pulmonary Vein Isolation Plus Left Atrial Slow Zone Mapping and Ablation An AcQMap Substrate Characterization Study (PLASZMA)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The AcQMap Imaging and Mapping System® is intended for use in patients for whom electrophysiology procedures have been prescribed.
When used with the AcQMap Catheters, the AcQMap System is intended to be used to reconstruct the selected chamber from ultrasound data for purposes of visualizing the chamber anatomy and displaying electrical impulses as either charge density-based or voltage-based maps of complex arrhythmias that may be difficult to identify using conventional mapping systems alone.
AND
When used with specified Patient Electrodes, the AcQMap System is intended to display the position of the AcQMap Catheters and conventional electrophysiology (EP) catheters in the heart.
OR
When used with conventional electrophysiology catheters, the AcQMap System provides information about the electrical activity of the heart and about catheter location during the procedure.
Study Type
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female ≥ 18 years of age at the time of consent
- Clinically indicated and scheduled for a de novo catheter ablation of a complex left atrial arrhythmia including AF/AT/AFL
- Willing and able to provide written informed consent to participate in the study and agree to comply with all follow-up visits and evaluations for the duration of the study.
Exclusion Criteria:
- In the opinion of the investigator, any contraindication to the planned atrial ablation, including anticoagulation contraindications, renal failure, or sepsis.
- Atrial arrhythmias secondary to electrolyte imbalance, thyroid disease, or any other reversible or non-cardiac cause.
- Any DCCV within 60-days of the index procedure where sinus rhythm was not maintained for at least 60-minutes.
- Any cardiac defibrillator (ICD) or pacemaker implanted within 8-weeks prior to the ablation procedure.
- History of previous left atrial ablation (including surgical treatment) for AF/AT/AFL.
Structural heart disease or cardiac history including:
- Left ventricular ejection fraction (LVEF) < 35% based on a 2-d transthoracic echocardiogram (TTE) within the previous 180-days prior to enrollment.
- Left atrial size > 60 mm (parasternal long-axis view) based on 2-d TTE within the previous 180-days prior to enrollment.
- Prior history of New York Heart Association (NYHA) Class IV heart failure.
- Any evidence of NYHA Class III heart failure in the previous 3-months prior to enrollment.
- Unstable angina or ongoing myocardial ischemia.
- Myocardial infarction (STEMI) within the previous 180-days (sub-endocardial infarct within previous 90-days) prior to enrollment.
- Moderate or severe valvular heart disease (stenosis or regurgitation).
- Presence of a left atrial appendage occlusion device.
- Body Mass Index (BMI) > 40kg/m2
- History of blood clotting or bleeding disease.
- History of chronic obstructive pulmonary disease (COPD) requiring use of oxygen in the treatment regimen.
- History of obstructive sleep apnea not currently being treated.
- Pregnant or lactating (current or anticipated during study follow-up).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Non-randomized
All subjects with de novo ablation procedure for an atrial arrhythmia using the AcQMap System.
|
Evaluate the safety and effectiveness of the AcQMap System in mapping atrial arrhythmias when a specific procedure work flow is followed.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Freedom From Device/Procedure Related Major Adverse Events (MAEs)
Time Frame: 6 Months
|
MAEs inlcude: death, myocardial infarction, cardiac perforation/tamponade, cerebral infarct, or systemic embolism, Major bleeding requiring transfusion of blood products, Mitral or tricuspid valve damage, Symptomatic pulmonary vein (PV) stenosis, Asymptomatic PV stenosis ≥ 70%, Permanent phrenic nerve injury, Access site complications requiring pharmacological or surgical intervention, Atrio-esophageal fistula, Pericarditis, Heart block requiring a permanent pacemaker, Vagal nerve injury leading to gastroparesis, Other serious adverse device effects (SADEs), including transient ischemic attack (TIAs), adjudicated as "probably or definitely related" to the AcQMap System
|
6 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Who Experienced at Least One procedure and device related Serious Adverse Events.serious adverse device effects (SADEs), and all unanticipated device effects (UADEs)
Time Frame: 6 Months
|
Recording of all SAEs/SADEs/UADEs through 6-months-procedure
|
6 Months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of subjects who are free from AF/AT/AFL (following a 90-day blanking period)
Time Frame: 12 Months
|
Time to first event of any atrial arrhythmia from day 91 through 12 months.
|
12 Months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLP-22
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Arrhythmias
-
TriVirum, Inc.CompletedAtrial Fibrillation | Arrhythmias, Cardiac | Paroxysmal Atrial Fibrillation | Afib | Irregular Heart Beat | Arrhythmia Atrial | Arrhythmias ParoxysmalUnited States
-
University Hospital, BordeauxCompletedVentricular Arrhythmias | Persistent Atrial FibrillationFrance
-
Abbott Medical DevicesCompletedCardiac Arrhythmia | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationSpain, United Kingdom, Germany, Italy, Austria, Czechia, France, Netherlands, Portugal
-
CathVision ApSMedicept IncActive, not recruitingCardiac Arrhythmia | Persistent Atrial FibrillationUnited States
-
Angelo BivianoCompleted
-
Barts & The London NHS TrustMedtronicCompletedCardiac Arrhythmia | Persistent Atrial FibrillationUnited Kingdom
-
University of Sao Paulo General HospitalMedtronicCompletedCardiac Arrythmias | Atrial Fibrillation ParoxysmalBrazil
-
Barts & The London NHS TrustNot yet recruitingInvestigation of Cardioversion Versus Therapeutic Ablation for Persistent AF (ORBICA-AF) (ORBICA-AF)Cardiac Arrhythmia | Persistent Atrial Fibrillation | Catheter Ablation
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
Medtronic Cardiac Rhythm and Heart FailureKing's College London; Deutsches Herzzentrum Muenchen; genae associates (CRO)...Completed
Clinical Trials on AcQMap High Resolution Imaging and Mapping System
-
Acutus MedicalCompletedRecurrent Atrial FibrillationUnited Kingdom, Netherlands, Germany, Canada, Czechia, Belgium
-
University of VirginiaBaylor College of Medicine; Stanford UniversityRecruitingGastroparesis | Lung Transplant; ComplicationsUnited States
-
Centre Hospitalier National d'Ophtalmologie des...RecruitingStroke | Glaucoma | Hypertension | Diabetes | Retinal Degeneration | Macular Edema | Retinitis Pigmentosa | Trauma | Dry Eye | Keratoconus | Retinal Detachment | Corneal Dystrophy | Vascular Inflammation | Macular Dystrophy | Maculopathy, Age RelatedFrance
-
Sheffield Children's NHS Foundation TrustRecruiting
-
Central Hospital, Nancy, FranceLorraine Cancer Institute - ICL; Emille Gallé Surgical Center - CCEG; Diagnostic...RecruitingBone Neoplasm | Soft Tissue NeoplasmFrance
-
Centre Hospitalier National d'Ophtalmologie des...RecruitingStroke | Glaucoma | Hypertension | Diabetes | Retinal Degeneration | Macular Edema | Retinitis Pigmentosa | Retinal Detachment | Vascular Inflammation | Macular Dystrophy | Maculopathy, Age RelatedFrance
-
Duke UniversityNational Institutes of Health (NIH); National Institute for Biomedical Imaging...CompletedBreast CancerUnited States
-
XEOS MedicalRecruitingBreast Cancer | Breast Cancer Invasive | Breast Cancer in SituBelgium
-
Karolinska University HospitalCompletedPneumonia | Sepsis | Critical Illness | Cognitive Impairment | Acute Respiratory Distress Syndrome | Extracorporeal Circulation; Complications | Long Term Adverse EffectsSweden
-
Asan Medical CenterMinistry of Health & Welfare, Korea; Bracco CorporateUnknownCerebral Arterial Diseases | Intimal Dissection | Dissecting Aneurysm of Cerebral ArteryKorea, Republic of